AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00504023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
Study NCT00504023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Punch biopsy and photography will be performed at the baseline and 12 week time points.
Study NCT00504023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
Study NCT02639637 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
Study NCT02639637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
Study NCT00787059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose (3%)
Study NCT02755155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human serum albumin infusion 4%
Description: Continuous infusion of 15mL/kg of bodyweight over 24h/day
Study NCT02755155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human serum albumin infusion 20%
Description: Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
Study NCT02069431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin spray
Description: Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
Study NCT02069431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo spray
Description: placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
Study NCT00313339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-coronary infusion
Description: In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
Study NCT01467414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily for 6 days
Study NCT04431583 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery- single surgeon service
Study NCT04431583 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery- multiple surgeon + multidisciplinary team approach
Study NCT04431583 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach
Study NCT02639637 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
Study NCT02639637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
Study NCT02639637 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neuropeptide Y
Description: During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
Study NCT02639637 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enalaprilat
Description: Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
Study NCT02639637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan 160mg
Description: Valsartan 160 mg/d for 7 days prior to one of the study days.
Study NCT03844139 — intervention group
Intervention type: DEVICE
Intervention: Feeding pump and glycerin syringe
Description: The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
Study NCT02329145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal denervation
Study NCT01307397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
Study NCT04298801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing
Description: A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.~If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours.
Study NCT04298801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician-directed diagnostic testing
Description: Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
Study NCT04298801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician-directed diagnostic testing
Description: Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
Study NCT01362205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT01362205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Inactive placebo (normal saline)
Study NCT02352675 — intervention group
Intervention type: OTHER
Intervention: Intraoperative Blood Sample
Description: Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
Study NCT02879305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
Study NCT02879305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEPO
Description: The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
Study NCT02879305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Study NCT02879305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Study NCT02879305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron therapy
Description: Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Study NCT02879305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron therapy
Description: Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Study NCT01236846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified Yogurt Drink
Description: Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
Study NCT01236846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain Yogurt Drink
Description: Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
Study NCT03640195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure
Description: Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day.
Study NCT02310113 — intervention group
Intervention type: OTHER
Intervention: NIRS
Description: Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
Study NCT01053325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Description: Daily prophylaxis with cotrimoxazole
Study NCT01053325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole prophylaxis
Description: Daily prophylaxis with cotrimoxazole
Study NCT01053325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP IPT
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine
Study NCT03665207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
Study NCT03665207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
Study NCT04039698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedicine monitoring and teleconsultation by video calls
Study NCT02097069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folic acid
Description: Folic acid 400 mcg/day
Study NCT02097069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: myo-inositol 2000 mg twice a day
Study NCT02097069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-Chiro-inositol
Description: D-chiro inositol 250 mg twice a day
Study NCT02097069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol plus D-chiro inositol
Description: Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
Study NCT04241952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Bedcycling
Study NCT02463448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells
Description: A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
Study NCT02545634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. helveticus R0052 and B. longum R0175
Description: See arm descriptions for intervention description.
Study NCT02545634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04678375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal diseases diagnosed by artificial intelligence algorithm
Description: An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
Study NCT01152398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-HER2
Description: experimental vaccine, subcutaneous injection q4weeks x6
Study NCT02670109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300mg/m2, IV, in 3 hours, during day -4
Study NCT02670109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 80mg/kg, IV, in 2 hours, during two days -2, -3
Study NCT02670109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 1400/m2, IV, in 1 hour, during day -3
Study NCT04039698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir/Sofosbuvir
Description: Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
Study NCT02670109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Transfusion, in 3 hours, during day 0
Study NCT02670109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 16mg/kg, Oral, during day -4
Study NCT03484910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
Study NCT03484910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
Study NCT02446340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalazatide
Description: Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
Study NCT02446340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
Study NCT03973034 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Low depth whole genome sequencing
Description: Low depth whole genome sequencing of the peripheral blood samples from different groups.
Study NCT03640299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS procedure
Description: Optimized preoperative, intraoperative and postoperative procedures.
Study NCT02006758 — intervention group
Intervention type: DEVICE
Intervention: EnligHTN™ Renal Denervation System
Description: The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
Study NCT00409838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
Study NCT00409838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, ≥ 15 mg, weekly, 6 months
Study NCT00409838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Tablets, Oral, ≥ 15 mg, weekly, 6 months
Study NCT00409838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
Study NCT00409838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution, intravenous, 10 mg/kg, every 28 days
Study NCT00409838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, oral, 15 mg weekly to be adjusted according to patient condition
Study NCT03177824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate 25Mg Tab
Description: Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
Study NCT03177824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
Study NCT02847715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePRIME
Description: ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
Study NCT02611609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem
Study NCT02611609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01433315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep restriction
Description: restricted sleep
Study NCT01057433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin (NK-104)
Description: pitavastatin (NK-104) 4 mg once daily (QD)
Study NCT01057433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: lopinavir/ritonavir 800 mg/200 mg
Study NCT03014518 — intervention group
Intervention type: OTHER
Intervention: Clinical assessments and blood samples; follow-up for 12 mos
Description: Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
Study NCT03014518 — intervention group
Intervention type: OTHER
Intervention: Clinical assessments and blood samples; no 12mo follow-up
Description: Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
Study NCT02320370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn DC Stimulator Plus tDCS
Description: transcranial electrical stimulation intervention with two experimental protocols
Study NCT03053401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
Study NCT03053401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
Study NCT03053401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
Study NCT01344278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
Study NCT00635232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: 300 mg (2 x 150 mg capsules) once daily for 12 weeks